Wockhardt Pharma Q4 sales up, stock soars by 7%

But barring these losses the company's earnings before tax and depreciation or EBIDTA improved by 35 % from 29%. The rises in margins are mainly on account of improved performance of the domestic formulation business and string of blockbuster drug launches in the US markets.

However few analysts were surprised by this jump. "There are hardly any institutional holders of Wockhardt stock, so it is interesting to see such big movement in the price", said Surjit Pal, Analyst Elara Capital.

Wockhardt last year had sold its nutrition business to French pharma giant Danone for Rs 1500cr, this gave the company enough cash to settle off its foreign currency bond holders and banks that had helped the company to restructure its loans. The company said it had to pay Rs 134 crore towards derivative settlement; CDR provision was at Rs 160 cr.